Pour une meilleure utilisation, nous vous conseillons d’activer Javascript dans votre navigateur.

Prostate Specific Antigen anticorps (AA 247-261)

PSA Reactivité: Humain WB Hôte: Lapin Polyclonal unconjugated

N° du produit ABIN289484

Fiche de données

Antigène Voir toutes Prostate Specific Antigen (PSA) Anticorps

Prostate Specific Antigen (PSA)
Épitope
16

6

5

5

5

5

5

4

3

2

2

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1
AA 247-261
Reactivité
181

15

10

5

4

1
Humain
Hôte
112

62

4

4

2
Lapin
Anticorps secondaires appropriés
Clonalité
124

60
Polyclonal
Conjugué
95

15

13

7

6

5

5

5

5

5

5

3

2

2

2

2

2

1

1

1

1

1

1

1
Cet anticorp Prostate Specific Antigen est non-conjugé
Application
87

71

37

33

26

23

23

13

12

9

8

8

8

5

4

3

2

2

2

2

2

2

2

1

1

1

1

1
Western Blotting (WB)

Purification

Affinity chromatography purified

Immunogène

KLK3 antibody was raised in rabbit using AA 247-261 [VHYRKWIKDTIVANP] of the human KLK3 protein as the immunogen.

Isotype

IgG

Top Product

Discover our top product PSA Anticorps primaire
anti-Prostate Specific Antigen (PSA) antibody
PSA Reactivité: Humain ELISA, WB, FACS, DB Hôte: Souris Monoclonal A5D5-1 unconjugated

anti-Prostate Specific Antigen (PSA) (AA 26-251) antibody
PSA Reactivité: Humain ELISA, WB, IHC, FACS Hôte: Souris Monoclonal 5A11E9 unconjugated

anti-Prostate Specific Antigen (PSA) (AA 1-100) antibody
PSA Reactivité: Humain WB, IHC, IF, IP Hôte: Lapin Polyclonal unconjugated

anti-Prostate Specific Antigen (PSA) antibody
PSA Reactivité: Humain ELISA, WB, IHC (p) Hôte: Souris Monoclonal A67-B-E3 unconjugated

anti-Prostate Specific Antigen (PSA) (AA 39-261) antibody
PSA Reactivité: Souris WB, IHC, IP, ICC Hôte: Lapin Polyclonal unconjugated

anti-Prostate Specific Antigen (PSA) antibody
PSA Reactivité: Humain IHC, StM, ISt Hôte: Lapin Monoclonal KLK3-2871R unconjugated Recombinant Antibody

anti-Prostate Specific Antigen (PSA) antibody
PSA Reactivité: Humain WB, IHC, IHC (p), FACS, ICC, IHC (fro), ELISpot Hôte: Souris Monoclonal C3F12 unconjugated

anti-Prostate Specific Antigen (PSA) (AA 150-250) antibody
PSA Reactivité: Humain IHC Hôte: Lapin Monoclonal MSVA-603R unconjugated Recombinant Antibody

anti-Prostate Specific Antigen (PSA) antibody (Biotin)
PSA Reactivité: Humain ELISA, WB, IHC (p) Hôte: Souris Monoclonal A67-B-E3 Biotin

anti-Prostate Specific Antigen (PSA) (AA 709-737), (C-Term) antibody
PSA Reactivité: Humain WB, IHC (p) Hôte: Lapin Polyclonal RB19102 unconjugated

Indications d'application

WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions

For Research Use only
Concentration

Lot specific

Buffer

Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Agent conservateur

Sodium azide

Précaution d'utilisation

This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation

Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock

4 °C/-20 °C

Stockage commentaire

Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.
Antigène

Prostate Specific Antigen (PSA)

Autre désignation

KLK3 (PSA Produits)

Synonymes

anticorps APS, anticorps KLK2A1, anticorps PSA, anticorps hK3, anticorps KLK3, anticorps Klk1c10l2, anticorps RSGK-50, anticorps RSKG-50, anticorps rGK-3, anticorps Kal-3, anticorps Kal3, anticorps Klk3, anticorps AAP-S, anticorps MP100, anticorps Psa, anticorps R74825, anticorps goku, anticorps kallikrein related peptidase 3, anticorps kallikrein 3, anticorps kallikrein 1-related peptidase C3, anticorps kallikrein B, plasma 1, anticorps aminopeptidase puromycin sensitive, anticorps KLK3, anticorps Klk1c3, anticorps Klkb1, anticorps Npepps

Sujet

Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. KLK 3 (also known as prostate specific antigen) is a marker for prostatic cancer and is involved in the pathogenesis and/or progression of prostate, breast, and possibly other malignancies.

Pathways

Système du Complément